Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients

Journal of Neuro-Oncology

Volumn 95, Issue 1, 2009, Pages 129-134

  Perry, Stephanie L ^a   Bohlin, Cindy ^a   Reardon, David A ^a   Desjardins, Annick ^a   Friedman, Allan H ^a   Friedman, Henry S ^a   Vredenburgh, James J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain tumors; Low molecular weight heparin; Malignant glioma; Tinzaparin; Venous thromboembolism

Indexed keywords

DEXAMETHASONE; IRINOTECAN; TEMOZOLOMIDE; TINZAPARIN;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIOTOMY; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIMARY PREVENTION; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADULT; AGED; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; GLIOMA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PULMONARY EMBOLISM; TOMOGRAPHY, X-RAY COMPUTED; VENOUS THROMBOEMBOLISM;

EID: 70349337128     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9911-7     Document Type: Article

References (35)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26. doi: 10.3322/canjclin.53.1.5
2. Akman F, Cooper RA, Sen M, Tanriver Y, Kentli S (2002) Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: How useful are prognostic indices in routine clinical practice? J Neurooncol 59:39-47. doi: 10.1023/ A:1016353614525
3. Mastronardi L, Guiducci A, Puzzilli F (2001) Proposal of a clinico-histological "glioma score" as a prognostic index in high-grade glioma patients. Preliminary observations in a series of 80 cases. J Neurosurg Sci 45:195-201 (discussion 201)
4. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/ NEJMoa043330
5. Chang S, Theodosopoulos P, Sneed P (2001) Multidisciplinary management of adult anaplastic astrocytomas. Semin Radiat Oncol 11:163-169. doi: 10.1053/srao.2001.21428
6. Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S (1999) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J Clin Oncol 17:3389-3395
7. ENOXACAN Study Group (1997) Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 84:1099-1103
8. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G (1998) Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339:80-85. doi: 10.1056/ NEJM199807093390204
9. Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH (2001) Deep vein thrombosis and its prevention in critically ill adults. Arch Intern Med 161:1268-1279. doi: 10.1001/archinte.161.10.1268
10. Chibbaro S, Tacconi L (2008) Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients. Surg Neurol 70:117-121. doi: 10.1016/ j.surneu.2007.06.081 (discussion 121)
11. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB (2001) Prevention of venous thromboembolism. Chest 119:132S-175S. doi: 10.1378/chest.119.1_suppl.132S
12. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, Hamilton PA (1996) A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 335:701-707. doi: 10.1056/NEJM199609053351003
13. Goldhaber SZ, Dunn K, Gerhard-Herman M, Park JK, Black PM (2002) Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 122:1933-1937. doi: 10.1378/ chest.122.6.1933
14. Green D, Lee MY, Ito VY, Cohn T, Press J, Filbrandt PR, VandenBerg WC, Yarkony GM, Meyer PR Jr (1988) Fixed- vs adjusted-dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA 260:1255-1258. doi: 10.1001/jama.260.9.1255
15. Iorio A, Agnelli G (2000) Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: A meta-analysis. Arch Intern Med 160:2327-2332. doi: 10.1001/ archinte.160.15.2327
16. Nurmohamed MT, Rosendaal FR, Buller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briet E (1992) Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis. Lancet 340:152-156. doi: 10.1016/0140-6736(92)93223-A
17. Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d'Azemar P, Buller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M (1996) Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 75:233-238
18. Ruff RL, Posner JB (1983) Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 13:334-336. doi: 10.1002/ ana.410130320
19. Weitz JI (1997) Low-molecular-weight heparins. N Engl J Med 337:688-698. doi: 10.1056/NEJM199709043371007
20. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Fiorentino MV (1997) Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study. Eur J Cancer 33:1592-1596. doi: 10.1016/S0959-8049(97)00167-6
21. Quevedo JF, Buckner JC, Schmidt JL, Dinapoli RP, O'Fallon JR (1994) Thromboembolism in patients with high-grade glioma. Mayo Clin Proc 69:329-332
22. Gerotziafas GT, Petropoulou AD, Verdy E, Samama MM, Elalamy I (2007) Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 5:955-962. doi: 10.1111/j.1538-7836.2007.02477.x
23. Brotman DJ, Deitcher SR, Lip GY, Matzdorff AC (2004) Virchow's triad revisited. South Med J 97:213-214. doi: 10.1097/ 01.SMJ.0000105663.01648.25
24. Bick RL (2003) Cancer-associated thrombosis. N Engl J Med 349:109-111. doi: 10.1056/NEJMp030086
25. Letai A, Kuter DJ (1999) Cancer, coagulation, and anticoagulation. Oncologist 4:443-449
26. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153. doi: 10.1056/NEJMoa025313
27. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY (1993) Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 43:1111-1114
28. Schmidt F, Faul C, Dichgans J, Weller M (2002) Low molecular weight heparin for deep vein thrombosis in glioma patients. J Neurol 249:1409-1412. doi: 10.1007/s00415-002-0855-5
29. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF (2008) Safety of anticoagulation use and bevacizumab in patients with glioma. Neurooncology 10:355-360. doi: 10.1215/15228517-2008-009
30. Perry JR, Rogers L, Laperriere N, Julian JA, Geerts WH, Agnelli G, Malkin M, Sawaya R, Baker R, Levine MN (2007) PRODIGE: A phase III randomized placebo-controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin (LMWH) in patients with newly diagnosed malignant glioma. J Clin Oncol 25:77s (Abstract 2011)
31. Lieu AS, Hwang SL, Howng SL, Chai CY (1999) Brain tumors with hemorrhage. J Formos Med Assoc 98:365-367
32. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S (2004) A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266-1271. doi: 10.1111/j.1538-7836.2004.00871.x
33. Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC (2004) Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948. doi: 10.1200/JCO.2004.10.002
34. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Buller HR (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23:2130-2135. doi: 10.1200/ JCO.2005.03.134
35. Lee AY, Rickles FR, Julian JA, Gent M, Baker RI, Bowden C, Kakkar AK, Prins M, Levine MN (2005) Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129. doi: 10.1200/ JCO.2005.03.133